Kura Oncology, Inc. (KURA) — SEC Financial Statements & Analysis

Kura Oncology, Inc. (KURA) is a pharmaceutical preparations company, incorporated in DE. Kura Oncology, Inc. trades on Nasdaq as: KURA. Kura Oncology, Inc. (KURA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Kura Oncology, Inc. carries a market cap of $974.74M, a P/E ratio of -3.28x, a P/B ratio of 20.13x, a P/S ratio of 12.62x, an enterprise value of $914.29M, and an EV/EBITDA multiple of -2.89x. On profitability, it posts an operating margin of -411.90%, a net margin of -384.30%, a Return on Equity (ROE) of -167.71%, a Return on Assets (ROA) of -46.73%, and a Return on Invested Capital (ROIC) of -157.70%. Per share, it reports EPS of $-3.34, diluted EPS of $-3.34, free cash flow per share of $-1.32, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 162.71% year-over-year, net income growth of 50.52% year-over-year, and EPS growth of 48.37% year-over-year. On the balance sheet, it maintains a current ratio of 4.73x, a quick ratio of 4.47x, working capital of $441.25M, a debt-to-equity ratio of 11.14x, a debt ratio of 0.92, an interest coverage ratio of -224.01x, free cash flow of $-117.43M (TTM), and net debt of $-60.45M. Figures sourced from SEC EDGAR.

Market Cap

$974.74M

P/E TTM

-3.28x

EPS TTM

$-3.34

P/B TTM

20.13x

ROE TTM

-167.71%

ROA TTM

-46.73%

Debt To Equity

11.14x

Free Cash Flow TTM

$-117.43M

Net Revenue TTM Growth 1Y

162.71%

Data as of 2026-06-30 · Source: SEC EDGAR